ponesimod

Showing 1 posts of 1 posts found.

J&J’s ponesimod meets primary and secondary endpoints at Phase 3 in relapsing multiple sclerosis

July 26, 2019
Medical Communications, Research and Development Johnson & Johnson, multiple sclerosis, pharma, ponesimod

New Phase 3 data has been released on Johnson & Johnson’s selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod, reporting that …

The Gateway to Local Adoption Series

Latest content